characterized to develop fibrosis, and in in vivo model on liver steatosis and metabolic disorder, to confirm the beneficial effect on metabolic health. Non-alcoholic steatohepatitis is the progressive form of NAFLD charac- terized by steatosis and inflammation. NAFLD can evolve into cirrhosis and, in some cases, to hepatocellular carci- noma.
The APPLIVER™ treatment shows a significant decrease of the cytokines production as TNF-α both in serum and in liver tissue, and of Collagen type 1 deposit level (fig.1). The severi- ty of hepatic fibrosis is the primary predictor of
and mortality in NAFLD patients. The pivotal role of hepatic stellate cells in liver fibrogenesis is well established and occurs by the activation and alter- ation of genes involved in the turno- ver of extracellular matrix compo- nents. The main risk factor can be identified in the liver fat deposit, indeed a healthy liver contains a small amount of fat. Steatosis is a common condition caused by having too much fat in the liver and it becomes a prob- lem when fat reaches 5% to 10% of liver's weight. The APPLIVER™ treat- ment shows that the liver fat accumu- lation (steatosis) is reduced as seen on the histological evaluation (fig.2). Moreover, it is known high that level of plasma cholesterol, triglycerides, or both, or a low high-density lipoprotein cholesterol level are risk factors to the development of atherosclerosis. In blood analysis, in our in vivo model, a significant decrease of the total cholesterol level
observed. Unexpectedly, during the Oral Glucose Tolerance Test the glucose level has also been reduced (fig.4). Our research studies confirm the beneficial effect on health of APPLIV- ER™ in metabolic disorder as NAFLD, dyslipidemia and hyperglicemia. So, this makes APPLIVER™ the perfect ingredient for dietary supplements and functional foods.
foods. (fig.3) was
liver-related morbidity
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112
